EB-3D

EB-3D is a potent and selective choline kinase α (ChoKα) inhibitor, with an IC50 of 1 μM for ChoKα1. EB-3D exerts effects on ChoKα expression, AMPK activation, apoptosis, endoplasmic reticulum stress and lipid metabolism. EB-3D exhibits a potent antiproliferative activity in a panel of T-leukemia cell lines. Anti-cancer activity[1][2][3].

Product Specifications

CAS Number

[1839150-63-8]

Product Name Alternative

(±)-CI-952,MKS 492

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

AMPK; Apoptosis

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/eb-3d.html

Concentration

10mM

Purity

99.64

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 9.09 mg/mL

Smiles

CN(C1=CC=[N+](CC2=CC=C(OCCOC3=CC=C(C[N+]4=CC=C(N(C)C)C=C4)C=C3)C=C2)C=C1)C.[Br-].[Br-]

Molecular Formula

C30H36Br2N4O2

Molecular Weight

644.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Mariotto E, et al. EB-3D a novel choline kinase inhibitor induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells. Biochem Pharmacol. 2018 Sep;155:213-223.|[2]Sola-Leyva A, et al. Choline kinase inhibitors EB-3D and EB-3P interferes with lipid homeostasis in HepG2 cells. Sci Rep. 2019 Mar 25;9 (1) :5109.|[3]Schiaffino-Ortega S, et al. Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1) .|[4]Mariotto E, et al. Choline Kinase Alpha Inhibition by EB-3D Triggers Cellular Senescence, Reduces Tumor Growth and Metastatic Dissemination in Breast Cancer. Cancers (Basel) . 2018;10 (10) :391. Published 2018 Oct 22.